Table 1.
Patient characteristics at baseline and by DVT history prior to starting therapy
| All patients n=32 | No DVT n=27 | DVT n=5 | p* | |
|---|---|---|---|---|
| Continuous variables | Median | Median | Median | |
| Age in years | 64 | 64 | 63 | n.s. |
| Prior therapies | 3 | 3 | 1 | n.s. |
| TNFα (pg/ml) | 28.2 | 26.2 | 28.2 | n.s. |
| CRP (<1 mg/dl) | 0.41 | 0.41 | 0.41 | n.s. |
| Thrombomodulin (μg/ml) | 95 | 104 | 85 | n.s. |
| VCAM (349–991 μg/ml) | 2390 | 2368 | 2562 | n.s. |
| D-dimer(<0.4μg/ml) | 0.43 | 0.42 | 0.5 | n.s. |
| Categorical variables | n | n | n | |
| Rai stage III-IV | 16 | 14 | 2 | n.s. |
| Bulky disease (LN >5 cm) | 23 | 21 | 2 | n.s. |
| Obesity (BMI>30) | 7 | 5 | 2 | n.s. |
| Venous catheter | 1 | 1 | 0 | n.s. |
| Cardiac disease | 2 | 2 | 0 | n.s. |
| Renal disease | 2 | 2 | 0 | n.s. |
| Positive lower extremity doppler | 0 | 0 | 0 | n.s. |
| Protein S low (55–134%) | 5 | 5 | 0 | n.s. |
| Protein C low (59–144%) | 0 | 0 | 0 | n.s. |
| Antithrombin low (57–137%) | 3 | 3 | 0 | n.s. |
| Factor V Leiden mutation (n=23) | 2 | 2 | 0 | n.s. |
| Prothrombine gene mutation (n=23) | 1 | 1 | 0 | n.s. |
*
The two-sided p-value for comparing each variable between patients with or without DVT prior to therapy.